Caplight Directory>Companies>Matisse Pharmaceuticals-preview>Matissepharmaceuticals


Matisse Pharmaceuticals

Matisse Pharmaceuticals

Private
GeleenN/Ahttps://www.matissepharmaceuticals.com/

Last Round

Grant

Jun 26, 2025

Total Funding Raised

$610,000

Momentum Score

50 /100

Company Overview

Matisse Pharmaceuticals is a biopharmaceutical company developing a treatment for sepsis.

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Matisse Pharmaceuticals Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Matisse Pharmaceuticals Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
GrantJun 26, 2025
VC RoundJan 4, 2024
VC RoundMar 1, 2020
SeedNov 15, 2016
View all Funding Rounds

Key People

Founding team and executive leadership

Kees Groen

Chief Executive Officer

Executive Team

Matisse Pharmaceuticals Investors

Notable investors and investment history

InvestorRounds
Mibiton FoundationSeed
Brightlands Life Sciences VenturesSeed
Eurostars SME programmeGrant
Brightlands Venture PartnersVC Round, Seed
Particon B.V.Seed
Netherlands Enterprise AgencyVC Round, Seed
Limburg Business Development FundVC Round, Seed
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 17, 2026

    Monthly visitors grew 176% MoM.

  • Feb 21, 2026

    Grew 67% QoQ, from 6 to 10 employees.

View all signals

Matisse Pharmaceuticals Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Matisse Pharmaceuticals Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Matisse Pharmaceuticals's valuation, stock price, and market status.

Firmographic Details

HeadquartersGeleen
Employee Range10
Year Founded2014
Last FundingJun 26, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.